PPT-Glycemic Management in Type 2 Diabetes

Efficacy and Safety of Modern Antihyperglycemic Therapies 1 DPP4 Inhibitors 2 DPP4 Inhibitors FDAApproved Agents Alogliptin Linagliptin Saxagliptin Sitagliptin Key Features Oral administration. Pharmacologic Management of Type 2 . Diabetes . Chapter 13. (Updated July 2015). William Harper, Maureen Clement, Ronald Goldenberg,. Amir Hanna, Andrea Main, . Ravi . Retnakaran. , . Diana . Sherifali,Vincent. 1. AACE Comprehensive Care Plan. 2. Handelsman Y, et al. . Endocr Pract. . 2011;17(suppl 2):1-53.. Glycemic Management in Type 2 Diabetes. Therapeutic Lifestyle Change. 3. Components of Therapeutic Lifestyle Change. 1. J. V Akinlotan, . 2. I.O Olayiwola, . 3. A Ladokun and . 4. S.A Sanni . 1. Nutrition and Dietetics Department, Moshood Abiola Polytechnic Abeokuta. 2,4. Nutrition and Dietetics Department, Federal University of Agriculture Abeokuta. Efficacy and Safety of Antihyperglycemic Therapies Introduced Since 2004. 1. DPP-4 Inhibitors. 2. FDA-Approved Agents. Alogliptin. Linagliptin. Saxagliptin. Sitagliptin. Key Features. Oral administration. Glimepiride, Metformin & . Voglibose. Combination in T2DM. Dr. Mohammed Riyaz . M.D (Medicine), Masters . in . Endocrinology(UK). Chief . Endocrinologist. & Medical Director (EDSC). Type 2 diabetes population requiring stringent . Help patients with type 2 diabetes achieve their glycemic goals. 1. In the US, diabetes is the primary diagnosis for . 37 million visits. to a physician’s office, emergency department or outpatient hospital-based clinic . National Center for Health in Public Housing Clinical Quality Working Group. Diabetes in PHPC Settings. HBA1c>9 in PHPC Settings. American Diabetes Association’s Press Release. The ADA has long recommended that treatment goals be individualized based on factors both modifiable and nonmodifiable, such as age, life expectancy, duration of disease, resources and support, and comorbid conditions. The ADA recommends that a reasonable A1C goal for many nonpregnant adults with type 2 diabetes is less than 7 percent based on the available evidence to date from the ACCORD, ADVANCE, VADT and UKPDS international clinical trials, which were evaluated and incorporated into ADA’s Standards of Care. . STANDARDS OF MEDICAL CARE IN DIABETES - 2019 Guidelines Update Ann Marie Blair, DNP, FNP, NP - C, BC - ADM, CDE Piedmont Columbus Regional Presenter Financial Relationships Disclosure Ann M. Blair, PortionCarbohydratesGIBreadsBread, pumpernickel1 slice11 gBread, white or wheat1 slice13 gBread, whole wheat1 slice14 gTortilla, corn1 (small)24 gTortilla, wheat1 (small)26 gCerealsBran buds1/3 cup18 INTRODUCTION The concept of the glycemic index (GI) wasintroduced as a means of classifying carbohydrate containingfoods based on the blood glucose response after food consump-tion. The GI is define 1. . This number is only set to grow, with a prevalence of 14% in the US forecasted for 2060. 2. . A chronic metabolic disorder characterized by persistent hyperglycemia, the disease can lead to hypertension, coronary artery disease, peripheral diabetic neuropathy, and may progress to high risk of myocardial infarction or stroke. TYPE 1 DM . Formerly known as juvenile-onset diabetes or insulin-dependent diabetes, accounts for about 5%-10% of all people with diabetes.. Type 1 diabetes generally affects people under 40 years of age, although it can occur at any age.. ●. . Section . was . renamed. ●. . . N. ew recommendation. : . using . reliable data . metrics. ●. . . D. iscussion on . the social determinants of . health. ●. . . Te. lemedicine role. Agent-Specific Considerations. Joshua J. Neumiller, PharmD, CDE, FAADE, FASCP. Vice-Chair & Associate Professor. College of Pharmacy and Pharmaceutical Sciences . Washington State University. Presenter Disclosure Information.